RAD001 in Combination With Cetuximab and Cisplatin in Recurrent and Metastatic SCCHN
Status:
Terminated
Trial end date:
2011-03-01
Target enrollment:
Participant gender:
Summary
1.Phase I: To estimate the Maximum Tolerated Dose (MTD) of RAD001 in combination with
cetuximab and cisplatin for treatment of metastatic squamous cell cancer of the head and neck
(SCCHN).
Secondary Objectives
1.To assess the toxicity of RAD001 in combination with weekly cetuximab and cisplatin on days
1 and 8 of each 28 day cycle in patients with recurrent or metastatic SCCHN,
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins